Zhengye Biotechnology Holding (ZYBT) Current Assets (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Current Assets for 3 consecutive years, with $19.4 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Assets fell 21.62% year-over-year to $19.4 million in Q4 2025; TTM through Dec 2025 was $19.4 million, a 21.62% decrease from a year earlier, with the FY2025 full-year figure at $19.6 million, down 19.23% from the prior year.
• Current Assets was $19.4 million for Q4 2025 at Zhengye Biotechnology Holding, down from $28.1 million in the prior quarter.
• Over five years, Current Assets peaked at $28.1 million in Q2 2025 and troughed at $19.4 million in Q4 2025.
• A 3-year average of $24.6 million and a median of $25.5 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets declined 5.95% in 2024 and decreased 21.62% in 2025, its largest moves.
• Over 3 years, Current Assets stood at $26.3 million in 2023, then declined by 5.95% to $24.7 million in 2024, then fell by 21.62% to $19.4 million in 2025.
• The last three Current Assets figures came in at $19.4 million (Q4 2025), $28.1 million (Q2 2025), and $24.7 million (Q4 2024), per Business Quant data.